Commentary|Videos|October 31, 2025

MATTERHORN Trial Findings Signal Paradigm Shift in Early Gastric Cancer Care

Learn how perioperative immunotherapy with Imfinzi is addressing long-standing unmet needs in gastric and GEJ cancers and paving the way for a new standard of care.

In a recent video interview with Applied Clinical Trials, Nancy Ghattas, VP, US Oncology Commercial Franchise Head of Immuno-Oncology, AstraZeneca, discussed the significance of the Phase III MATTERHORN trial (NCT04592913) results for patients with early-stage or locally advanced gastric and gastroesophageal junction (GEJ) cancers. She highlighted how the Imfinzi-based perioperative regimen demonstrated a 22% reduction in the risk of death and improved overall survival regardless of PD-L1 status, marking the first immunotherapy in this setting to show such benefit. Ghattas emphasized the trial’s potential to establish a new standard of care in gastric and GEJ cancers and reflected on how these findings align with AstraZeneca’s broader immuno-oncology strategy to bring curative-intent treatments to patients earlier in their cancer journey.

The below interview transcript was lightly edited for clarity.

ACT: This is the first perioperative immunotherapy regimen to demonstrate an OS benefit in this population. What are the potential implications for shifting the standard of care in gastric and GEJ cancers?

Ghattas: For the last 20 years, as I mentioned, there’s been no major advancement in this space beyond surgery and chemotherapy—and that has been associated with poor prognosis as well. Patients tend to relapse within the first two years, and only about one out of four survive beyond five years. So there has been a huge unmet need.

Now, with the MATTERHORN data, we’ve seen that when we start with Imfinzi—or an IO—in a perioperative setting, which basically means adding immunotherapy to chemotherapy before and after surgery, with maintenance immunotherapy afterward, we are seeing a meaningful change: an overall survival benefit of 22%.

This represents a paradigm shift—an advancement that we expect will become the new standard of care for early gastric cancer and early gastroesophageal cancers.


Related to this article

What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.